Physician profile
Janet Guisinger
NPI 1295773208
$8,851.24
in general payments reported to CMS, 2019-2025
42 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $641 · 2021: $1,302 · 2022: $2,258 · 2023: $937 · 2024: $1,364 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,490.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,232.06 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,214.80 | 2020-2025 | |
| Lilly USA, LLC | $1,161.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $757.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $382.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $371.55 | 2022-2025 | Caplyta |
| Pfizer INC. | $327.97 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $301.07 | 2019-2024 | Vpriv |
| Bayer Healthcare Pharmaceuticals INC. | $257.27 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.08 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $242.80 | 2019-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $231.09 | 2019-2023 | Seglentis, Livalo |
| Allergan, INC. | $184.99 | 2019-2020 | |
| Astellas Pharma US INC | $172.56 | 2019-2025 | Veozah |
| Axsome Therapeutics, INC. | $164.34 | 2023-2025 | Auvelity |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Guisinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.